Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).

Hidetoshi Kawaguchi ,Shigehira Saji ,Yoshiaki Ito ,Tomomi Fujisawa ,Norikazu Masuda ,Kenjiro Aogi ,Seigo Nakamura ,Masao Hattori ,Shoichiro Ohtani ,Keisei Anan ,Nobuaki Sato ,Yutaka Yamamoto ,Toshinari Yamashita ,Satoshi Morita ,Yoshio Miki ,Eriko Tokunaga ,Yoshie Hasegawa ,Takahiro Nakayama ,Shinji Ohno ,Masakazu Toi

doi:10.1007/s10549-017-4212-x

Abstract

This retrospective study evaluated the effect of clinical background and treatment line on time to treatment failure (TTF) in advanced/metastatic breast cancer (AMBC) patients receiving F500 in Japan (UMIN 000015168). Patients who commenced F500 treatment were registered at 16 sites in Japan. Correlations between baseline clinicopathological factors, treatment line, and TTF were investigated by Kaplan-Meier analysis. TTF data were analyzed using univariate analysis and multivariate analysis with a Cox proportional hazards model. Data for 1072 patients were available; 1031 patients (96.2%) were evaluable for efficacy. F500 was administered as first-line treatment in 2.0%, second-line in 22.7%, third-line in 26.7%, and≥fourth-line in 48.6% patients. Median TTF was 5.4months. Multivariate analysis found that earlier F500 use (first and second vs. third vs.≥fourth line; hazard ratio (HR)=0.80, 95% confidence interval (CI)0.74-0.86; P<0.001), longer period from AMBC diagnosis to F500 use (≥3 vs.<3years; HR0.60, 95% CI0.51-0.70; P<0.001), and no prior palliative chemotherapy administered for unresectable or metastatic breast cancer (no vs. yes; HR0.69, 95% CI0.60-0.80; P<0.001) were associated with significantly longer TTF. Among 691 patients, where information on histologic/nuclear grade was available, a low grade was also associated with a longer TTF, but this finding was not maintained among patients with recurrent breast cancer (N=558). Among women with recurrent breast cancer, a longer DFI between a patient's initial breast cancer diagnosis and their recurrence was associated with a longer TTF on F500 therapy. Our study showed that treatment period of F500 was longer when used in earlier-line treatment. For patients on F500, TTF was also longer for patients who had not received prior palliative chemotherapy and for those who had a longer period from their AMBC diagnosis to F500 use.

Full Text